Kirchmeier Marc, Fluckiger Anne-Catherine, Soare Catalina, Bozic Jasminka, Ontsouka Barthelemy, Ahmed Tanvir, Diress Abebaw, Pereira Lenore, Schödel Florian, Plotkin Stanley, Dalba Charlotte, Klatzmann David, Anderson David E
VBI Vaccines, Cambridge, Massachusetts, USA.
Clin Vaccine Immunol. 2014 Feb;21(2):174-80. doi: 10.1128/CVI.00662-13. Epub 2013 Dec 11.
A prophylactic vaccine to prevent the congenital transmission of human cytomegalovirus (HCMV) in newborns and to reduce life-threatening disease in immunosuppressed recipients of HCMV-infected solid organ transplants is highly desirable. Neutralizing antibodies against HCMV confer significant protection against infection, and glycoprotein B (gB) is a major target of such neutralizing antibodies. However, one shortcoming of past HCMV vaccines may have been their failure to induce high-titer persistent neutralizing antibody responses that prevent the infection of epithelial cells. We used enveloped virus-like particles (eVLPs), in which particles were produced in cells after the expression of murine leukemia virus (MLV) viral matrix protein Gag, to express either full-length CMV gB (gB eVLPs) or the full extracellular domain of CMV gB fused with the transmembrane and cytoplasmic domains from vesicular stomatitis virus (VSV)-G protein (gB-G eVLPs). gB-G-expressing eVLPs induced potent neutralizing antibodies in mice with a much greater propensity toward epithelial cell-neutralizing activity than that induced with soluble recombinant gB protein. An analysis of gB antibody binding titers and T-helper cell responses demonstrated that high neutralizing antibody titers were not simply due to enhanced immunogenicity of the gB-G eVLPs. The cells transiently transfected with gB-G but not gB plasmid formed syncytia, consistent with a prefusion gB conformation like those of infected cells and viral particles. Two of the five gB-G eVLP-induced monoclonal antibodies we examined in detail had neutralizing activities, one of which possessed particularly potent epithelial cell-neutralizing activity. These data differentiate gB-G eVLPs from gB antigens used in the past and support their use in a CMV vaccine candidate with improved neutralizing activity against epithelial cell infection.
非常需要一种预防性疫苗,以防止人类巨细胞病毒(HCMV)在新生儿中的先天性传播,并减少HCMV感染的实体器官移植免疫抑制受者中危及生命的疾病。针对HCMV的中和抗体可提供针对感染的显著保护,而糖蛋白B(gB)是此类中和抗体的主要靶标。然而,过去的HCMV疫苗的一个缺点可能是它们未能诱导出高滴度的持续性中和抗体反应,从而无法预防上皮细胞感染。我们使用包膜病毒样颗粒(eVLPs),其中颗粒是在小鼠白血病病毒(MLV)病毒基质蛋白Gag表达后在细胞中产生的,以表达全长CMV gB(gB eVLPs)或与水泡性口炎病毒(VSV)-G蛋白的跨膜和细胞质结构域融合的CMV gB的完整细胞外结构域(gB-G eVLPs)。表达gB-G的eVLPs在小鼠中诱导出强效中和抗体,其对上皮细胞中和活性的倾向比可溶性重组gB蛋白诱导的要强得多。对gB抗体结合滴度和T辅助细胞反应的分析表明,高中和抗体滴度并非仅仅由于gB-G eVLPs的免疫原性增强。用gB-G而非gB质粒瞬时转染的细胞形成了多核体,这与感染细胞和病毒颗粒的预融合gB构象一致。我们详细检测的五种gB-G eVLPs诱导的单克隆抗体中有两种具有中和活性,其中一种具有特别强效的上皮细胞中和活性。这些数据将gB-G eVLPs与过去使用的gB抗原区分开来,并支持将它们用于具有改善的针对上皮细胞感染的中和活性的CMV疫苗候选物。